Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES
收藏DataMed2026-07-12 收录
官方服务：
资源简介：
The current study aims to explore the clinical effects and mechanistics of mono- and combination therapy with SGLT-2 inhibitor empagliflozin and DPP-4 inhibitor linagliptin on renal physiology and biomarkers in metformin-treated T2DM patients.
提供机构：
ClinicalTrials.gov
